HTG Molecular Diagnostics (HTGM) versus Agilent Technologies (A) Financial Survey

HTG Molecular Diagnostics (NASDAQ: HTGM) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Dividends

Agilent Technologies pays an annual dividend of $0.60 per share and has a dividend yield of 1.0%. HTG Molecular Diagnostics does not pay a dividend. Agilent Technologies pays out 25.4% of its earnings in the form of a dividend. Agilent Technologies has increased its dividend for 2 consecutive years.

Analyst Ratings

This is a summary of recent ratings and price targets for HTG Molecular Diagnostics and Agilent Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HTG Molecular Diagnostics 0 0 2 0 3.00
Agilent Technologies 0 1 11 0 2.92

HTG Molecular Diagnostics presently has a consensus target price of $7.00, suggesting a potential upside of 114.72%. Agilent Technologies has a consensus target price of $72.81, suggesting a potential upside of 17.74%. Given HTG Molecular Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe HTG Molecular Diagnostics is more favorable than Agilent Technologies.

Institutional & Insider Ownership

39.4% of HTG Molecular Diagnostics shares are held by institutional investors. 7.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

HTG Molecular Diagnostics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Valuation and Earnings

This table compares HTG Molecular Diagnostics and Agilent Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HTG Molecular Diagnostics $14.76 million 6.27 -$18.96 million ($1.79) -1.82
Agilent Technologies $4.47 billion 4.42 $684.00 million $2.36 26.20

Agilent Technologies has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HTG Molecular Diagnostics and Agilent Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
HTG Molecular Diagnostics -105.56% -338.96% -66.49%
Agilent Technologies 5.02% 18.01% 9.80%

Summary

Agilent Technologies beats HTG Molecular Diagnostics on 10 of the 17 factors compared between the two stocks.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq lymphoma panel; HTG EdgeSeq microRNA whole-transcriptome assay; and HTG EdgeSeq DLBCL cell of origin assay. It also provides sample processing and molecular profiling of retrospective cohorts through its VERI/O laboratory; and designs custom panels for biopharmaceutical customers and research services, resulting from research and development collaboration agreements with biopharmaceutical customers. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company has a research collaboration with Insituto Valenciano de Oncologia on breast cancer recurrence risk. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Agilent Technologies Company Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment services; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, and compliance support, as well as asset management and consultation services. The company markets its products through direct sales, electronic commerce, resellers, manufacturers' representatives, and distributors. It has collaboration with the University of Southern California Michelson Center for Convergent Bioscience. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply